Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

The Market Online’s Weekly Cannabis Report – Aug. 23, 2024

Jonathon Brown Jonathon Brown, The Market Online
0 Comments| August 23, 2024

{{labelSign}}  Favorites
{{errorMessage}}

Canopy Growth’s chief executive officer, David Klein, will be retiring at the end of its current fiscal year, March 31, 2025. He took on the role in January 2020, and during his tenure Canopy Growth laid the groundwork for leading the cannabis market across multiple regions by transitioning to an asset-light model in Canada and several international markets.

Click to enlarge
(Source: Canopy Growth Corp.).

Click here for the full story.

Weekly Update – Top Cannabis News Stories

1 | PharmaDrug’s Sairiyo Therapuetics announces independent screening identifying Cepharanthine’s potential to bind to monkeypox proteins

2 | Nextleaf provides an update on its commercial partners program

3 | Herbal Dispatch reports solid Q2 2024 financial results

Click to enlarge

Top Cannabis Stocks Aug. 16 to Aug. 22, 2024

1. T.TLRY | 13,365 views | Tilray Brands Inc.
2. T.WEED | 4,945 views | Canopy Growth Corp
3.C.CURA | 4,523 views | Curaleaf Holdings Inc.
4. T.LABS | 3,581 views | Medipharm Labs Corp.
5. T.OGI | 1,654 views | Organigram Holdings Inc.
6.C.OILS | 694 views | Nextleaf Solutions Ltd.


The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.




{{labelSign}}  Favorites
{{errorMessage}}